News for Zai Lab Limited (9688.HK)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational onco

Zai Lab Limited (ZLAB) is presenting promising data at the AACR 2025 on two innovative oncology therapies, ZL-6201 and ZL-1222. ZL-6201 is advancing int

Zai Lab (ZLAB) is set to present phase 1 trial data for its DLL3-targeted ADC, ZL-1310, at the 2025 ASCO Annual Meeting. The trial focuses on patients w

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial [url="](NCT06179069)[/url] eval

Zai Lab Limited (ZLAB) has received a significant boost as China's National Medical Products Administration has accepted its supplemental new drug application f

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug

China's NMPA has accepted Zai Lab's sNDA for repotrectinib to treat NTRK fusion-positive solid tumors. Repotrectinib targets adult patients with solid t

Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on

Insiders, including top executives, sold $1.65 million in Zai Lab shares, yet the stock price surged by 56.87% over the past year. Analysts maintain a "

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Thursday's session foll...

We recently published a list of 10 Stocks Insiders Sold in April After Trump’s Tariff Rollout.

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Argan, Inc. AGX rose sharply during Friday's session following ...

U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday. Shares of Concentrix Corporation CNXC rose sharply during Thursday's session ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic partnerships positioning it as a 2025 Buy.

ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. Read more about ZLAB stock here.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Appl

The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.